{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T16:36:05Z","timestamp":1793723765100,"version":"4.6.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T00:00:00Z","timestamp":1681862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T00:00:00Z","timestamp":1681862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The FIGHT-203 study is sponsored by Incyte Corporation (Wilmington, DE, USA)."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1038\/s41375-023-01859-3","type":"journal-article","created":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T08:05:21Z","timestamp":1681891521000},"page":"981-987","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Comprehensive response criteria for myeloid\/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: a proposal from the MLN International Working Group"],"prefix":"10.1038","volume":"37","author":[{"given":"William","family":"Shomali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philomena","family":"Colucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5478-7847","authenticated-orcid":false,"given":"Tracy I.","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Jacques","family":"Kiladjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"Langford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay L.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7718-6507","authenticated-orcid":false,"given":"Andreas","family":"Reiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro M.","family":"Vannucchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8253-6156","authenticated-orcid":false,"given":"Jason","family":"Gotlib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,19]]},"reference":[{"key":"1859_CR1","unstructured":"Myeloid\/lymphoid neoplasms with eosinophilia and gene rearrangement. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., (eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th Edition, 2. Lyon, France: International Agency for Research on Cancer; 2017."},{"key":"1859_CR2","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and histiocytic\/dendritic neoplasms. Leukemia. 2022;36:1703\u201319.","journal-title":"Leukemia"},{"key":"1859_CR3","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200\u201328.","journal-title":"Blood"},{"key":"1859_CR4","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1093\/ajcp\/aqaa208","volume":"155","author":"O Pozdnyakova","year":"2021","unstructured":"Pozdnyakova O, Orazi A, Kelemen K, King R, Reichard KK, Craig FE, et al. Myeloid\/lymphoid neoplasms associated with eosinophilia and rearrangements of PDGFRA, PDGFRB, or FGFR1 or with PCM1-JAK2. Am J Clin Pathol. 2021;155:160\u201378.","journal-title":"Am J Clin Pathol"},{"key":"1859_CR5","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.6004\/jnccn.2020.0042","volume":"18","author":"AT Gerds","year":"2020","unstructured":"Gerds AT, Gotlib J, Bose P, Deininger MW, Dunbar A, Elshoury A, et al. Myeloid\/Lymphoid neoplasms with Eosinophilia and TK fusion genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw. 2020;18:1248\u201369.","journal-title":"J Natl Compr Cancer Netw"},{"key":"1859_CR6","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1182\/blood-2016-10-695973","volume":"129","author":"A Reiter","year":"2017","unstructured":"Reiter A, Gotlib J. Myeloid neoplasms with eosinophilia. Blood. 2017;129:704\u201314.","journal-title":"Blood"},{"key":"1859_CR7","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1080\/10245332.2018.1446279","volume":"23","author":"K Umino","year":"2018","unstructured":"Umino K, Fujiwara SI, Ikeda T, Toda Y, Ito S, Mashima K, et al. Clinical outcomes of myeloid\/lymphoid neoplasms with fibroblast growth factor receptor-1 (FGFR1) rearrangement. Hematology. 2018;23:470\u20137.","journal-title":"Hematology"},{"key":"1859_CR8","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1080\/10428194.2017.1397663","volume":"59","author":"P Strati","year":"2018","unstructured":"Strati P, Tang G, Duose DY, Mallampati S, Luthra R, Patel KP, et al. Myeloid\/lymphoid neoplasms with FGFR1 rearrangement. Leuk Lymphoma. 2018;59:1672\u20136.","journal-title":"Leuk Lymphoma"},{"key":"1859_CR9","doi-asserted-by":"publisher","first-page":"3778","DOI":"10.1182\/blood.V98.13.3778","volume":"98","author":"A Demiroglu","year":"2001","unstructured":"Demiroglu A, Steer EJ, Heath C, Taylor K, Bentley M, Allen SL, et al. The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins. Blood. 2001;98:3778\u201383.","journal-title":"Blood"},{"key":"1859_CR10","doi-asserted-by":"publisher","first-page":"S66","DOI":"10.1016\/S2152-2650(21)01213-1","volume":"21","author":"A Reiter","year":"2021","unstructured":"Reiter A, Cross NC, Gotlib J. Myeloid\/lymphoid neoplasms with eosinophilia and TKI fusion genes: treatment. Clin Lymphoma Myeloma Leuk. 2021;21:S66\u2013S68. Suppl 1.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1859_CR11","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/ajh.26352","volume":"97","author":"W Shomali","year":"2022","unstructured":"Shomali W, Gotlib J. World Health Organization\u2013defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022;97:129\u201348.","journal-title":"Am J Hematol"},{"key":"1859_CR12","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1182\/bloodadvances.2019001111","volume":"4","author":"G Metzgeroth","year":"2020","unstructured":"Metzgeroth G, Schwaab J, Naumann N, Jawhar M, Haferlach T, Fabarius A, et al. Treatment-free remission in FIP1L1-PDGFRA\u2013positive myeloid\/lymphoid neoplasms with eosinophilia after imatinib discontinuation. Blood Adv. 2020;4:440\u20133.","journal-title":"Blood Adv"},{"key":"1859_CR13","unstructured":"PEMAZYRE\u2122 (pemigatinib) tablets, for oral use [prescribing information]. Incyte Corporation, Wilmington, DE, 2022."},{"key":"1859_CR14","first-page":"448","volume":"1","author":"A Goradia","year":"2008","unstructured":"Goradia A, Bayerl M, Cornfield D. The 8p11 myeloproliferative syndrome: review of literature and an illustrative case report. Int J Clin Exp Pathol. 2008;1:448\u201356.","journal-title":"Int J Clin Exp Pathol"},{"key":"1859_CR15","doi-asserted-by":"publisher","first-page":"3136","DOI":"10.1182\/bloodadvances.2020002308","volume":"4","author":"M Kasbekar","year":"2020","unstructured":"Kasbekar M, Nardi V, Dal Cin P, Brunner AM, Burke M, Chen YB, et al. Targeted FGFR inhibition results in a durable remission in an FGFR1-driven myeloid neoplasm with eosinophilia. Blood Adv. 2020;4:3136\u201340.","journal-title":"Blood Adv"},{"key":"1859_CR16","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/bjh.16294","volume":"188","author":"T Wang","year":"2020","unstructured":"Wang T, Wang Z, Zhang L, Wen L, Cai W, Yang X, et al. Identification of a novel TFG-FGFR1 fusion gene in an acute myeloid leukaemia patient with t(3;8)(q12;p11). Br J Haematol. 2020;188:177\u201381.","journal-title":"Br J Haematol"},{"key":"1859_CR17","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1080\/15384047.2016.1210727","volume":"17","author":"Y Wang","year":"2016","unstructured":"Wang Y, Wu X, Deng J, Yu H, Xu R, Zhu Z, et al. Diagnostic application of next-generation sequencing in ZMYM2-FGFR1 8p11 myeloproliferative syndrome: a case report. Cancer Biol Ther. 2016;17:785\u20139.","journal-title":"Cancer Biol Ther"},{"key":"1859_CR18","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1182\/blood.V126.23.2812.2812","volume":"126","author":"S Kreil","year":"2015","unstructured":"Kreil S, Ad\u00e8s L, Bommer M, Stegelmann F, Ethell ME, Lubking A, et al. Limited efficacy of ponatinib in myeloproliferative neoplasms associated with FGFR1 fusion genes [abstract]. Blood. 2015;126:2812.","journal-title":"Blood"},{"key":"1859_CR19","doi-asserted-by":"publisher","first-page":"14479","DOI":"10.1073\/pnas.0404438101","volume":"101","author":"J Chen","year":"2004","unstructured":"Chen J, Deangelo DJ, Kutok JL, Williams IR, Lee BH, Wadleigh M, et al. PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. Proc Natl Acad Sci USA. 2004;101:14479\u201384.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1859_CR20","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1182\/blood-2021-148103","volume":"138","author":"J Gotlib","year":"2021","unstructured":"Gotlib J, Kiladjian J-J, Vannucchi A, Rambaldi A, Reiter A, Shomali W, et al. A phase 2 study of pemigatinib (FIGHT-203; INCB054828) in patients with myeloid\/lymphoid neoplasms (MLNs) with fibroblast growth factor receptor 1 (FGFR1) rearrangement (MLNFGFR1) [abstract]. Blood. 2021;138:385.","journal-title":"Blood"},{"key":"1859_CR21","doi-asserted-by":"publisher","first-page":"e0231877","DOI":"10.1371\/journal.pone.0231877","volume":"15","author":"PCC Liu","year":"2020","unstructured":"Liu PCC, Koblish H, Wu L, Bowman K, Diamond S, DiMatteo D, et al. INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models. PLoS One. 2020;15:e0231877.","journal-title":"PLoS One"},{"key":"1859_CR22","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.annonc.2022.02.001","volume":"33","author":"V Subbiah","year":"2022","unstructured":"Subbiah V, Iannotti NO, Gutierrez M, Smith DC, Feliz L, Lihou CF, et al. FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF\/FGFR alterations and advanced malignancies. Ann Oncol. 2022;33:522\u201333.","journal-title":"Ann Oncol"},{"key":"1859_CR23","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1182\/blood-2014-10-607341","volume":"125","author":"MR Savona","year":"2015","unstructured":"Savona MR, Malcovati L, Komrokji R, Tiu RV, Mughal TI, Orazi A, et al. An international consortium proposal of uniform response criteria for myelodysplastic\/myeloproliferative neoplasms (MDS\/MPN) in adults. Blood. 2015;125:1857\u201365.","journal-title":"Blood"},{"key":"1859_CR24","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059\u201368.","journal-title":"J Clin Oncol"},{"key":"1859_CR25","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, B\u00fcchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424\u201347.","journal-title":"Blood"},{"key":"1859_CR26","doi-asserted-by":"publisher","first-page":"100806","DOI":"10.1016\/j.blre.2021.100806","volume":"48","author":"RM Shallis","year":"2021","unstructured":"Shallis RM, Pollyea DA, Zeidan AM. The complete story of less than complete responses: the evolution and application of acute myeloid leukemia clinical responses. Blood Rev. 2021;48:100806.","journal-title":"Blood Rev"},{"key":"1859_CR27","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.3390\/ijms22062983","volume":"22","author":"W Shomali","year":"2021","unstructured":"Shomali W, Gotlib J. Response criteria in advanced systemic mastocytosis: evolution in the era of KIT inhibitors. Int J Mol Sci. 2021;22:2983.","journal-title":"Int J Mol Sci"},{"key":"1859_CR28","unstructured":"Foucar K, Reichard K, Czuchlewski D Bone Marrow Pathology. Chicago, IL: American Society for Clinical Pathology Press; 2019."},{"key":"1859_CR29","first-page":"1128","volume":"90","author":"J Thiele","year":"2005","unstructured":"Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005;90:1128\u201332.","journal-title":"Haematologica"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01859-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01859-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01859-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T10:58:16Z","timestamp":1683716296000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01859-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,19]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["1859"],"URL":"https:\/\/doi.org\/10.1038\/s41375-023-01859-3","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,19]]},"assertion":[{"value":"2 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"WS has received research support from Incyte Corporation and Blueprint Medicines; has received consultancy fees from or participated on advisory boards for Blueprint Medicines and Incyte Corporation. PC is a former employee and stock owner of Incyte Corporation. TIG has received consultancy fees from or participated on advisory boards for Blueprint Medicines, Celgene\/Bristol Myers Squibb, Cogent Biosciences, and Incyte Corporation. J-JK is a member of an entity\u2019s Board of Directors or advisory committees for AbbVie, AOP Health, Bristol Myers Squibb, Incyte Corporation, and Novartis. CL has received consultancy fees from Blueprint Medicines, Cogent Biosciences, and Incyte Corporation. JLP has received consultancy fees from or participated on advisory boards for Astellas Pharma, Celgene\/Bristol Myers Squibb, and Incyte Corporation. AR has received honoraria from, is a member of an entity\u2019s Board of Directors or advisory committees for, and received other (travel expenses) and research funding from AOP Health, Blueprint Medicines, Celgene\/Bristol Myers Squibb, GlaxoSmithKline, Novartis; is a member of an entity\u2019s Board of Directors or advisory committees and received research funding from AbbVie; and received honoraria and other (travel expenses) from Incyte Corporation. AMV received honoraria from and is a member of an entity\u2019s Board of Directors or advisory committees for Bristol Myers Squibb, Incyte Corporation, and Novartis; and is a member of an entity\u2019s Board of Directors or advisory committees for AbbVie. JG received research funding from Blueprint Medicines, Deciphera, and Incyte Corporation; received consultancy fees from or participated on advisory boards for Allakos, Blueprint Medicines, Deciphera, Incyte Corporation, and Novartis.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}